Elite Cardiovascular Leaders Unite: Driving Innovation Through Shared Excellence Oak Ridge, TN, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall'24 Conference being held at the Gaylord Rockies Resort & Convention Center in Aurora, CO, October 17-19, 2024. The CV Transforum is the leading conference for cardiovascular organizational performance ...

Oak Ridge, TN, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Maxim Director of Research and Senior Healthcare Analyst Anthony Vendetti. The summit is being held from October 15 – 17, 2024. Event: Fireside Chat at 2024 Maxim Healthcare Virtual Summit Date: Tuesday, October 15, 2024 Time: 10: ...

Company to Focus on 510(k) Approval Path, Accelerating Time-to-Market Oak Ridge, TN, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces a strategic update to its regulatory approach for its novel diagnostic blood volume analyzer platform. Following productive discussions with the U.S. Food and Drug Administration (FDA), the company has decided to withdraw its current dual 510(k)/CLIA-waiver application and resubmit a ...

Oak Ridge, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces its participation in the Annual Scientific Meeting of the Heart Failure Society of America (HFSA), taking place September 27-30 at the Georgia World Congress Center and Signia by Hilton Atlanta. The event will gather the world's top heart failure experts. Key meeting highlights: Exclusive showcase of BVA at the HFSA 'Devices in Heart Failure: From Mecha ...

Core Insights - Daxor Corporation has launched the ezBVA Lab program in partnership with a leading 1,000+ bed comprehensive medical center in western Florida to enhance blood volume analysis capabilities [1][2] - The ezBVA Lab service offers rapid 24-hour testing, aimed at optimizing heart failure treatment outcomes and reducing associated costs [1][2] - Daxor's BVA diagnostic provides 98% accurate data for individualized fluid management, which is crucial for improving patient outcomes in heart failure care [3] Company Overview - Daxor Corporation is recognized as the global leader in blood volume measurement technology, with the BVA-100™ being the only FDA-cleared diagnostic blood test for quantifying blood volume status [4] - Over 65,000 tests have been conducted at leading hospitals in the U.S., significantly reducing mortality and readmissions in heart failure and critical care [4] - The company is engaged in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [4]

Oak Ridge, TN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh. Dear Valued Shareholders, I am pleased to present our mid-year update for our unaudited first half results of 2024, highlighting Daxor Corporation's remarkable progress and financial performance. Our commitment to innovation in blood volume ana ...

Oak Ridge, TN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 26th Annual Global Investment Conference being held on September 9-11, 2024 in New York City at the Lotte New York Palace Hotel. The presentation will be available on-demand beginning September 9, 2024 at 7:00 AM ET. Investors who wish to listen to the Company's presentation ca ...

Community Hospital Purchases BVA Analyzer With Focus on Improving Outpatient Heart Failure Care Oak Ridge, TN, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces the expansion of its blood volume analysis (BVA) technology through the acquisition of the BVA analyzer. This advancement not only enhances revenue streams, but also sets the stage for projected accelerated sales growth for the rest of the year. A rural 339-bed comm ...

Oak Ridge, TN, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it has been awarded a $1.9M two-year contract from the U.S. Air Force (USAF) to support the continued development of a novel fluorescent tracer and optical sensing technology into a next-generation point-of-care blood volume analyzer for military and civilian applications. Michael Feldschuh, Daxor's President and CEO, highlighted the significance of this ...

Core Insights - Daxor Corporation is expanding its blood volume analysis (BVA) services with the launch of the ezBVA lab service in three new facilities, anticipating sustained accelerated sales growth for the remainder of the year [1][3] Company Developments - Recent sales achievements include the adoption of Daxor's ezBVA Lab service by a leading full-service medical center in Georgia, a purchase by a hospital in North Carolina that is part of the largest non-profit health system, and implementation by a top-rated hospital in Central Florida [2] - The ezBVA lab service is a CLIA certified facility that provides next-day blood volume analysis results, enhancing patient care while managing healthcare expenses [3] Technology and Impact - Daxor's BVA-100® is the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition, with over 65,000 tests performed across leading U.S. hospital centers [4] - The technology has shown significant benefits in reducing mortality and readmissions in heart failure and critical care patients, indicating its critical role in fluid management [4]